Funded Biomarker Testing
45 items
Reflex testing to confirm or exclude small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
Funded Biomarker Disease Site: Ovary
Biomarker: SMARCA4
Testing Method:Panel
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Trillium Health Partners, University Health Network, William Osler Health System
Reflex tumour testing for all patients diagnosed with high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Funded Biomarker Disease Site: Ovary
Biomarker: BRCA1, BRCA2
Testing Method:Panel
Testing Site: Hamilton Health Sciences, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System
Repeat FLT3 testing of adult patients with relapsed or refractory acute myeloid leukemia being considered for therapy with Gilteritinib.
Funded Biomarker Disease Site: Hematology
Biomarker: FLT3
Testing Method:Sequencing
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, St. Joseph's Healthcare Hamilton, The Ottawa Hospital, University Health Network
Review of tumour by a subspecialist Pathologist for classification
Funded Biomarker Disease Site: Soft Tissue
Biomarker:
Testing Method:
Testing Site: Hamilton Health Sciences, Mount Sinai Hospital, The Ottawa Hospital
Serous (high grade/advanced) endometrial carcinoma where HER2 directed therapy is being considered.
Funded Biomarker Disease Site: Endometrium
Biomarker: HER2
Testing Method:In Situ Hybridization (ISH)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System
Testing on advanced/metastatic breast cancer where directed therapy is being considered.
Funded Biomarker Disease Site: Breast
Biomarker: ESR1, PIK3CA
Testing Method:Panel
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System
Testing on patients previously diagnosed with locally advanced or metastatic NSCLC who have progressed on or after EGFR TKI therapy.
Funded Biomarker Disease Site: Lung
Biomarker: Acquired EGFR T790M
Testing Method:Sequencing
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System
Testing on previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) where FGFR2 directed therapy is being considered
Funded Biomarker Disease Site: Hepatobiliary
Biomarker: FGFR2
Testing Method:Sequencing
Testing Site: Hamilton Health Sciences, Hospital for Sick Children (SickKids), London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System
Testing to support diagnosis of sex-cord stromal tumours.
Funded Biomarker Disease Site: Ovary
Biomarker: DICER1, FOXL2
Testing Method:Panel
Testing Site: Hamilton Health Sciences, Kingston Health Sciences Centre, London Health Sciences Centre, Trillium Health Partners, University Health Network
Pages
- « First
- ‹ Previous
- 1
- 2
- 3
- 4